Drug

Cabazitaxel

Approved · EMA

ClassTubulin inhibitorEmerging researchLate-stage development

Also known as Jevtana, 1-HYDROXY-7.BETA.,10.BETA.-DIMETHOXY-9-OXO-5.BETA.,20-EPOXYTAX-11-ENE-2.ALPHA.,4,13.ALPHA.-TRIYL 4-ACETATE 2-BENZOATE 13-((2R,3S)-3-(((TERT-BUTOXY)CARBONYL)AMINO)-2-HYDROXY-3-PHENYLPROPANOATE), Cabazitaxelum.

RxNorm996051 ChEMBLCHEMBL1201748 ATCL01CD04UNII51F690397J

Research papers

Active clinical trials

Protein targets

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase 1b Study of JNJ-78278343, Targeting Human Kallikrein 2 (KLK2) in Combination With Other Agents for Metastatic Prostate Cancer

Clinical trial2026-07-06Results expected Q3 2027 · ClinicalTrials.gov

A Phase III, Multicentre, Randomised Controlled Study to Evaluate the Efficacy and Safety of AZD2265 (FPI-2265) ²²⁵Ac-PSMA-I&T Compared With Standard of Care in Patients With PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Clinical trial2026-07-01Results expected Q1 2029 · ClinicalTrials.gov

A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Clinical trial2026-06-25Results expected Q1 2030 · ClinicalTrials.gov

Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer

Clinical trial2026-06-20Primary completion · ClinicalTrials.gov

Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial

Clinical trial2026-06-18Results posted · ClinicalTrials.gov

Randomized Phase II Study of Platinum-Taxane-Cetrelimab Induction Followed by Niraparib Plus or Minus Cetrelimab Maintenance in Men With Aggressive Variant Prostate Cancers

Clinical trial2026-06-12Results expected Q4 2027 · ClinicalTrials.gov

Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carboplatin Induction Chemotherapy in Men With Aggressive Variant Prostate Cancer (AVPC)

Clinical trial2026-06-10Completed · ClinicalTrials.gov

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

Clinical trial2026-06-08Results expected Q3 2027 · ClinicalTrials.gov

Approval: Cabazitaxel Accord (EMA)

Regulatory2020-08-28EMA

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.

Research2019-09-30The New England journal of medicine

Drug Safety Update: Cabazitaxel (Jevtana▼): risk of medication error resulting in overdose

Regulatory2014-12-11MHRA

Approval: Jevtana (EMA)

Regulatory2011-03-17EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Cabazitaxel

Aliases & brands

Jevtana1-HYDROXY-7.BETA.,10.BETA.-DIMETHOXY-9-OXO-5.BETA.,20-EPOXYTAX-11-ENE-2.ALPHA.,4,13.ALPHA.-TRIYL 4-ACETATE 2-BENZOATE 13-((2R,3S)-3-(((TERT-BUTOXY)CARBONYL)AMINO)-2-HYDROXY-3-PHENYLPROPANOATE)Cabazitaxelum

RxNorm CUI

996051

ChEMBL ID

CHEMBL1201748

ATC codes

L01CD04

UNII

51F690397J

Primary mechanism

Tubulin inhibitor

Regulatory jurisdictions

emamhra

Pharmacology & targets

15 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Tubulin beta-4B chain

TUBB4B · P68371

INHIBITORTubulin inhibitor

Tubulin beta-1 chain

TUBB1 · Q9H4B7

INHIBITORTubulin inhibitor

Tubulin alpha-3C chain

TUBA3C · P0DPH7

INHIBITORTubulin inhibitor

Tubulin alpha-4A chain

TUBA4A · P68366

INHIBITORTubulin inhibitor

Tubulin beta-3 chain

TUBB3 · Q13509

INHIBITORTubulin inhibitor

Tubulin alpha-1A chain

TUBA1A · Q71U36

INHIBITORTubulin inhibitor

Tubulin beta-4A chain

TUBB4A · P04350

INHIBITORTubulin inhibitor

Tubulin beta-8 chain

TUBB8 · Q3ZCM7

INHIBITORTubulin inhibitor

Tubulin beta chain

TUBB · P07437

INHIBITORTubulin inhibitor

Tubulin alpha-1B chain

TUBA1B · P68363

INHIBITORTubulin inhibitor

Tubulin alpha-1C chain

TUBA1C · Q9BQE3

INHIBITORTubulin inhibitor

Tubulin alpha-3E chain

TUBA3E · Q6PEY2

INHIBITORTubulin inhibitor

Tubulin beta-2A chain

TUBB2A · Q13885

INHIBITORTubulin inhibitor

Tubulin beta-2B chain

TUBB2B · Q9BVA1

INHIBITORTubulin inhibitor

Tubulin beta-6 chain

TUBB6 · Q9BUF5

INHIBITORTubulin inhibitor

Regulatory timeline

3 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

2011-03-17

Latest approval

2020-08-28

Authorities

EMA · MHRA

Total events

emaEuropean Medicines Agency· 2 events

2020-08-28Approval

Approval: Cabazitaxel Accord (EMA)

Indication: Treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

Evidence ↗

2011-03-17Approval

Approval: Jevtana (EMA)

Indication: Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a… Show full indication

Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

Evidence ↗

mhraMedicines and Healthcare products Regulatory Agency· 1 event

2014-12-11Safety communicationSafety

Drug Safety Update: Cabazitaxel (Jevtana▼): risk of medication error resulting in overdose

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).

Clinical trials

91 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 91

Phase 112Phase 1 / 29Phase 253Phase 2 / 33Phase 313Phase 41

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Phase IV, Multicenter, National, Non-comparative, Open-label Study of Cabazitaxel, Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Second-line Treatment of Patients With Metastatic Castration-resistant Prostate Cancer and After Failure of Docetaxel-based Chemotherapy. Descriptive Assessment of the Circulating Tumor Cells in This Context.

CompletedPH IVSanofin=452016

A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

Active, not recruitingPH IIIUNICANCERn=7612041

A Phase III Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature

RecruitingPH IIISWOG Cancer Research Networkn=5282034

RecruitingPH IIIAmgenn=7502032

RecruitingPH IIIAstraZenecan=6702029

Recent completions

Trials that read out recently, adding to the completed evidence base.

Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carboplatin Induction Chemotherapy in Men With Aggressive Variant Prostate Cancer (AVPC)

CompletedPH IIM.D. Anderson Cancer Centern=962026

A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate Cancer

CompletedPH IIMasonic Cancer Center, University of Minnesotan=612025

A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer

CompletedPH IIBristol-Myers Squibbn=3512025

A Prospective Phase II Trial of Cabazitaxel in Male Patients With Chemotherapy Pre-treated Metastatic Nonseminomatous Germ-cell Tumors

CompletedPH IIGustave Roussy, Cancer Campus, Grand Parisn=342023

A Phase II, Open-label, Study to Assess the Efficacy, Safety, and Tolerability of AZD4635 in Combination With Durvalumab and in Combination With Cabazitaxel and Durvalumab in Patients Who Have Progressive Metastatic Castrate-Resistant Prostate Cancer (AARDVARC)

CompletedPH IIAstraZenecan=302022

A Randomized, Open Label, Phase IIB Trial of Optimal Sequencing of Treatment Options for Poor Risk Metastasized Castration Resistant Prostate Cancer Previously Treated With Docetaxel

CompletedPH II/IIIThe Netherlands Cancer Instituten=1002022

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.

The New England journal of medicine · 2019 · 439 cites

Related drugs

3 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Abiraterone

Studied across the same disease area as Cabazitaxel in the shared literature.

1 shared disease1 shared paper

Enzalutamide

Studied across the same disease area as Cabazitaxel in the shared literature.

1 shared disease1 shared paper

Prednisone

Studied across the same disease area as Cabazitaxel in the shared literature.

1 shared disease1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials
Regulatory event sources are credited in the Regulatory Timeline above.